Chemical industry – Page 102
-
Business
BASF to move pigments production to Asia
Firm will cut 650 jobs, close UK plant and expand in China and Korea
-
BusinessPharma manufacturing woes dog industry
Regulators are stepping up inspections, and discovering ever more problems
-
Business
Counterfeit anxiety pills seized in Switzerland
1 million fake tablets were en route from China to Egypt
-
Business
Roche backs biologics boom
Swiss firm to invest heavily in manufacturing for complex biological drugs
-
-
BusinessIneos raises axe over Grangemouth petrochemicals
Facility set to close without pension reforms and government help to fund ethane shipping terminal
-
BusinessGSK to apply for malaria vaccine approval
Infection protection drops over time, but the firm will go ahead with regulatory submission
-
Business
Solvay expands surfactants business with Chemlogics buyout
$1.3bn deal brings firm into booming US oil and gas drilling market
-
BusinessAmid huge cuts, Merck vows research focus
8500 more jobs to be axed, but the drugmaker ‘remains committed to innovation’
-
Business
Lundbeck cuts jobs in Europe, but expands in US
Depression drug approval fuels US recruitment
-
Business
Aspen acquires anticoagulant brands
South African drugmaker buys thrombosis drugs from GSK for £700m
-
Business
Japan confirms Novartis clinical trial data fabrication
Investigation into blood pressure blockbuster continues
-
Business
Clariant expands into China
Firm buys pigments arm of Jiangsu Multicolor and will build new plant
-
Business
Norway abandons full-scale CCS project
Technology development centre will receive extra funding
-
Business
Algal oil producer steps up supply
Solazyme to provide 10,000 tonnes of tailored oil to Unilever
-
Business
Nanobody inflammation drug attracts Abbvie
$840m licensing deal shows support for antibody fragments
-
BusinessNew respiratory drugs neck and neck
Combination inhalers from GSK and Novartis approved in EU and Japan
-
CareersNon-profit pharma
Not-for-profit drug discovery is growing into a promising niche employment opportunity within the pharmaceutical industry. James Mitchell Crow investigates